Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Evolus, Inc. - Common Stock (NQ:EOLS)

11.99 -0.04 (-0.33%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Evolus, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Final Phase 2 Data Evaluating 40U Dose of PrabotulinumtoxinA-xvfs to be Presented at 2023 ASDS Annual Meeting
From Evolus
Via Business Wire
7 Must-Own Small-Cap Stocks That Could Outperform the Market
If you’re ready to absorb significant risk for the chance of ridiculous upside, these small-cap stocks to buy may be just for you. 
Via InvestorPlace
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
7 Small-Cap Stocks Analysts Predict Will Double in 2024
While small-cap stocks to buy present exceptional risk, they also offer tremendous rewards for intrepid retail investors. 
Via InvestorPlace
Earnings Preview: Evolus
Via Benzinga
5 Analysts Have This to Say About Evolus
Via Benzinga
Evolus Inc. (NASDAQ: EOLS) Highlighted for Surprising Price Action
Via Investor Brand Network
Evolus to Participate in September Conferences
From Evolus
Via Business Wire
Evolus Announces Inducement Grants for New Chief Marketing Officer
From Evolus
Via Business Wire
Evolus Appoints Tomoko Yamagishi-Dressler as Chief Marketing Officer
From Evolus
Via Business Wire
Over $15M Bet On Impinj? Check Out These 4 Stocks Insiders Are Buying
Although U.S. stocks closed lower on Tuesday, there were a few notable insider trades. 
Via Benzinga
Why Shares of Evolus Are Jumping Thursday
The stock climbed on record second-quarter revenue and a raise in full-year guidance. 
Via The Motley Fool
Expert Ratings for Evolus
Via Benzinga
This Analyst Likes Evolus As 'Top Play In Aesthetics'
Evolus Inc (NASDAQ: EOLS) will be the exclusive U.S. 
Via Benzinga
Stonegate Capital Partners Announces Publishing of a Thematic Report - Undervalued Growth Pharma Companies Amidst Healthcare Sector Decline
Dallas, Texas--(Newsfile Corp. - August 8, 2023) - Stonegate is pleased to announce the... 
Via Newsfile
Evolus Unveils New Branding for Flagship Product Jeuveau® to Reflect Growing and Evolving Consumers
From Evolus
Via Business Wire
Evolus Reports Second Quarter 2023 Results and Provides Business Update
From Evolus
Via Business Wire
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Expert Ratings for Evolus
Via Benzinga
Evolus: Q1 Earnings Insights
Via Benzinga
Why Willis Towers Watson Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers Femasys Inc. (NASDAQ: FEMY) gained 54% to $0.55. Femasys reported a notice of allowance for new U.S. patent application covering use of FemBloc for female permanent birth control. 
Via Benzinga
Comcast, STMicroelectronics, Lam Research, Meta Platforms And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded higher, with the Nasdaq Composite gaining around 200 points on Thursday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Evolus Raises Full-Year Revenue Guidance on Record Second Quarter 2023 Revenue
From Evolus
Via Business Wire
Evolus to Participate in Canaccord Genuity’s 43rd Annual Growth Conference
From Evolus, Inc.
Via Business Wire
Evolus to Report Second Quarter 2023 Results and Provide Business Update
From Evolus
Via Business Wire
Twitter Faces Threats From AI and Threads
AI is changing the open internet landscape, and Meta's new Threads app is looking to take a bite out of Twitter's audience. 
Via The Motley Fool
Evolus Launches Nuceiva® (botulinum toxin type A) in Italy
From Evolus
Via Business Wire
Evolus Announces Successful Completion of Phase 2 Study Evaluating “Extra-Strength” Dose of Jeuveau ®
From Evolus
Via Business Wire
Evolus Reaches 1 Million Redemptions in its Evolus Rewards™ Patient Loyalty Program
From Evolus
Via Business Wire
Evolus Reports First Quarter 2023 Results and Provides Business Update
From Evolus
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.